Arbutus Biopharma price target lowered to $6 from $7.50 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arbutus Biopharma to $6 from $7.50 and keeps a Buy rating on the shares post the Q3 results.